Forward P/S Multiple: TransMedics Group, Inc. (TMDX)
TransMedics Group (TMDX) growth is driven by the expansion of organ preservation systems and logistical precision. A monopoly position in air transport ensures a stable cash flow, while the uniqueness of the technology provides the pricing power to dictate service costs to the market. On GURU.Markets, the forward revenue multiple illustrates the business valuation trend, with the parameter stabilizing at 7.40, confirming the high market value of the company's innovations.
Summary analytical data breakdowns for TransMedics Organ Care System (TMDX)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital TransMedics Group|TMDX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital TransMedics Group|TMDX - Company Aggregate Debts|Debt to Book Capitalization Ratio TransMedics Organ Care System|TMDX - Company Long-Term Debt|Company Current Liabilities TransMedics|Quick Ratio transmedics.com
- financial results and valuation multiples details:
TMDX - Company Net Income|Expected Profit TransMedics Group|TMDX - Market Cap to Net Income Ratio|Projected Price to Earnings TransMedics Group, Inc.|TMDX - PEG Multiple|EV/EBITDA Multiple TransMedics Organ Care System|TMDX - Operating income before deduction of amortization|Earnings per share for the last twelve months TransMedics|TMDX - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months transmedics.com|TMDX - Net earnings per share growth this year|Earnings growth forecast for next year TransMedics Group
- sales and revenue indicators:
Fundamental company analysis:TMDX (TransMedics)
To select high-quality assets, it is essential for an investor to compare the current market value of a business with its future cash flows. This forward price-to-sales valuation measures the ratio of market capitalization to projected sales, which, for a market-monopolizing ecosystem like TransMedics Group (TMDX), allows for an assessment of the premium for implementing live organ storage standards through an analysis of this chart's dynamics.
Who TransMedics Group competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ATEC|Forward Price-to-Revenue Multiple Artivion Corp AORT|Forward P/S Multiple ENOV (Enovis Corporation)|Forward P/S Multiple integralife.com IART|ESTA - Price-to-Projected Revenue Ratio|BBNX: Price-to-Projected Revenue Ratio|IRMD (Iradimed) - Forward Price-to-Revenue Multiple|Embecta Health - Forward Price to Sales|TNDM (Tandem Diabetes Care) - Forward P/S Multiple|Market Cap to Future Revenue Ratio axogeninc.com AXGN|Price-to-Projected Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Projected Price to Revenue|Bioventus Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - Forward P/S Multiple|Market Cap to Expected Sales Ratio blade.com SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Inc)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|VANI (vivani.com) - Forward Price-to-Revenue Multiple|XTNT: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|MODD: Forward Price to Sales|Forward P/S Multiple MYO|Forward P/S Multiple Envoy Medical Inc (COCH)|Price-to-Projected Revenue Ratio Vivos Therapeutics VVOS|NVNO: Market Cap to Projected Revenue|SINT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Tenon Medical Inc. TNON|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Autonomix Medical|IVF (INVO Fertility Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio bonebiologics.com BBLG|Forward P/S Multiple AXNX|BIOLASE Inc. - Market Cap to Projected Revenue|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO Bio - Forward P/S Multiple
